CINCINNATI, June 15 /PRNewswire-FirstCall/ — Kendle
(Nasdaq: KNDL), a leading, global full-service clinical
research organization, today announced it now offers Brain Network
Activation (BNA) imaging providing a non-invasive platform for
mapping, monitoring and understanding brain electro-physiological
network activity in response to cognitive or physiological stimuli.
The BNA imaging technology was developed by ElMindA, a medical
technology development company based in Herzliya, Israel. Exclusively licensed to Kendle’s
early stage development efforts, this innovative solution reveals
electrophysiological neural networks by using an innovative set of
signal processing and pattern recognition techniques that combine
the high temporal resolution of EEG with the spatial resolution of
fMRI. The result is a three-dimensional image of neuronal
connectivity and synchronization providing sensitive, specific and
reproducible data on drug effects essential for early stage
development.
“This technology represents a sizeable step forward in our
ability to evaluate the effectiveness of CNS drugs early in their
development by directly and objectively observing the brain’s
response to them,” said Ed Sellers,
MD, PhD, FRCPC, FACP, Vice President, Early Stage, Kendle.
“BNA is faster, less expensive and more accessible than other
brain imaging solutions currently on the market because all
scanning can be done in house. Ultimately this translates
into powerful, abundant data and expedited go/no-go decisions for
our customers, saving them time and money.”
The BNA technology utilizes standard 64 electrode EEG and can be
applied in any clinic by an E
‘/>”/>
